DGS Capital Management LLC Buys Shares of 10,477 Medifast, Inc. (NYSE:MED)

DGS Capital Management LLC acquired a new stake in shares of Medifast, Inc. (NYSE:MED) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,477 shares of the specialty retailer’s stock, valued at approximately $401,000. DGS Capital Management LLC owned about 0.10% of Medifast at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. AQR Capital Management LLC lifted its position in Medifast by 18.7% during the third quarter. AQR Capital Management LLC now owns 121,671 shares of the specialty retailer’s stock valued at $9,107,000 after purchasing an additional 19,192 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Medifast by 22.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 166,210 shares of the specialty retailer’s stock worth $12,441,000 after buying an additional 30,329 shares during the last quarter. UBS Group AG grew its holdings in shares of Medifast by 7.5% in the third quarter. UBS Group AG now owns 75,784 shares of the specialty retailer’s stock worth $5,672,000 after acquiring an additional 5,309 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of Medifast by 301.1% in the fourth quarter. Exchange Traded Concepts LLC now owns 18,666 shares of the specialty retailer’s stock worth $1,255,000 after acquiring an additional 14,012 shares during the period. Finally, Pacer Advisors Inc. increased its position in Medifast by 62.9% during the fourth quarter. Pacer Advisors Inc. now owns 522,732 shares of the specialty retailer’s stock valued at $35,138,000 after acquiring an additional 201,752 shares during the last quarter. 95.51% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, DA Davidson cut Medifast from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $25.00 to $17.50 in a research report on Wednesday, June 5th.

Medifast Price Performance

Shares of NYSE:MED opened at $21.14 on Friday. The firm’s 50 day simple moving average is $24.72 and its two-hundred day simple moving average is $40.97. The company has a market capitalization of $231.27 million, a P/E ratio of 3.41 and a beta of 1.16. Medifast, Inc. has a 1-year low of $18.81 and a 1-year high of $109.52.

Medifast (NYSE:MED) last issued its earnings results on Monday, April 29th. The specialty retailer reported $0.66 earnings per share for the quarter, missing the consensus estimate of $0.78 by ($0.12). Medifast had a return on equity of 36.64% and a net margin of 7.55%. The firm had revenue of $174.74 million during the quarter, compared to the consensus estimate of $168.90 million. During the same period in the prior year, the company posted $3.67 EPS. The company’s quarterly revenue was down 49.9% on a year-over-year basis. On average, sell-side analysts anticipate that Medifast, Inc. will post 0.94 earnings per share for the current fiscal year.

Medifast Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.